Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 496

1.

A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.

Ciosi M, Maxwell A, Cumming SA, Hensman Moss DJ, Alshammari AM, Flower MD, Durr A, Leavitt BR, Roos RAC; TRACK-HD team; Enroll-HD team, Holmans P, Jones L, Langbehn DR, Kwak S, Tabrizi SJ, Monckton DG.

EBioMedicine. 2019 Oct 4. pii: S2352-3964(19)30624-3. doi: 10.1016/j.ebiom.2019.09.020. [Epub ahead of print]

2.

Multimodal characterization of the visual network in Huntington's disease gene carriers.

Gregory S, Odish OFF, Mayer I, Mills J, Johnson EB, Scahill RI, Rothwell J, Rees G, Long JD, Tabrizi SJ, Roos RAC, Orth M.

Clin Neurophysiol. 2019 Aug 28;130(11):2053-2059. doi: 10.1016/j.clinph.2019.08.018. [Epub ahead of print]

PMID:
31541982
3.

Repeat variations in polyglutamine disease-associated genes and cognitive function in old age.

Gardiner SL, Trompet S, Sabayan B, Boogaard MW, Jukema JW, Slagboom PE, Roos RAC, van der Grond J, Aziz NA.

Neurobiol Aging. 2019 Aug 9. pii: S0197-4580(19)30280-5. doi: 10.1016/j.neurobiolaging.2019.08.002. [Epub ahead of print]

4.

Association of CAG Repeats With Long-term Progression in Huntington Disease.

Langbehn DR, Stout JC, Gregory S, Mills JA, Durr A, Leavitt BR, Roos RAC, Long JD, Owen G, Johnson HJ, Borowsky B, Craufurd D, Reilmann R, Landwehrmeyer GB, Scahill RI, Tabrizi SJ; TRACK-HD and Track-On HD Groups.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2368. [Epub ahead of print]

PMID:
31403680
5.

Prevalence of Carriers of Intermediate and Pathological Polyglutamine Disease-Associated Alleles Among Large Population-Based Cohorts.

Gardiner SL, Boogaard MW, Trompet S, de Mutsert R, Rosendaal FR, Gussekloo J, Jukema JW, Roos RAC, Aziz NA.

JAMA Neurol. 2019 Jun 1;76(6):650-656. doi: 10.1001/jamaneurol.2019.0423.

PMID:
30933216
6.

The prevalence and the burden of pain in patients with Huntington disease: a systematic review and meta-analysis.

Sprenger GP, van der Zwaan KF, Roos RAC, Achterberg WP.

Pain. 2019 Apr;160(4):773-783. doi: 10.1097/j.pain.0000000000001472.

PMID:
30889051
7.

Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials.

Müller HP, Huppertz HJ, Dreyhaupt J, Ludolph AC, Tabrizi SJ, Roos RAC, Durr A, Landwehrmeyer GB, Kassubek J.

Parkinsonism Relat Disord. 2019 Jun;63:179-184. doi: 10.1016/j.parkreldis.2019.02.004. Epub 2019 Feb 5.

PMID:
30846243
8.

Visual Object Perception in Premanifest and Early Manifest Huntington's Disease.

Coppen EM, Jacobs M, van der Zwaan KF, Middelkoop HAM, Roos RAC.

Arch Clin Neuropsychol. 2019 Feb 23. pii: acz002. doi: 10.1093/arclin/acz002. [Epub ahead of print]

PMID:
30796801
9.

Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?

Quarrell OWJ, Nance MA, Nopoulos P, Reilmann R, Oosterloo M, Tabrizi SJ, Furby H, Saft C, Roos RAC, Squitieri F, Landwehrmeyer GB, Burgunder JM; Juvenile Huntington Disease Working Group of the European Huntington Disease Network.

Mov Disord. 2019 Apr;34(4):584-585. doi: 10.1002/mds.27640. Epub 2019 Feb 20. No abstract available.

PMID:
30788860
10.

Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.

Winder JY, Achterberg WP, Gardiner SL, Roos RAC.

Eur J Neurol. 2019 May;26(5):780-785. doi: 10.1111/ene.13889. Epub 2019 Jan 27.

PMID:
30576046
11.

Assessment Scales for Patients with Advanced Huntington's Disease: Comparison of the UHDRS and UHDRS-FAP.

Winder JY, Achterberg WP, Marinus J, Gardiner SL, Roos RAC.

Mov Disord Clin Pract. 2018 Aug 24;5(5):527-533. doi: 10.1002/mdc3.12646. eCollection 2018 Sep-Oct.

12.

Altered Intracortical T1-Weighted/T2-Weighted Ratio Signal in Huntington's Disease.

Rowley CD, Tabrizi SJ, Scahill RI, Leavitt BR, Roos RAC, Durr A, Bock NA.

Front Neurosci. 2018 Nov 5;12:805. doi: 10.3389/fnins.2018.00805. eCollection 2018.

13.

EEG may serve as a biomarker in Huntington's disease using machine learning automatic classification.

Odish OFF, Johnsen K, van Someren P, Roos RAC, van Dijk JG.

Sci Rep. 2018 Oct 31;8(1):16090. doi: 10.1038/s41598-018-34269-y.

14.

Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification.

Winder JY, Roos RAC, Burgunder JM, Marinus J, Reilmann R.

Mov Disord Clin Pract. 2018 Apr 15;5(3):290-295. doi: 10.1002/mdc3.12618. eCollection 2018 May-Jun.

15.

Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset.

Gardiner SL, Milanese C, Boogaard MW, Buijsen RAM, Hogenboom M, Roos RAC, Mastroberardino PG, van Roon-Mom WMC, Aziz NA.

Neurol Genet. 2018 Oct 4;4(5):e275. doi: 10.1212/NXG.0000000000000275. eCollection 2018 Oct.

16.

Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease.

Gardiner SL, Harder AVE, Campman YJM, Trompet S, Gussekloo J, van Belzen MJ, Boogaard MW, Roos RAC, Jansen IE, Pijnenburg YAL, Scheltens P, van der Flier WM, Aziz NA.

Neurobiol Aging. 2019 Jan;73:230.e9-230.e17. doi: 10.1016/j.neurobiolaging.2018.09.007. Epub 2018 Sep 15.

PMID:
30314815
17.

Predictors of simulated driving performance in Huntington's disease.

Jacobs M, Hart EP, Mejia Miranda Y, Groeneveld GJ, van Gerven JMA, Roos RAC.

Parkinsonism Relat Disord. 2019 Mar;60:64-69. doi: 10.1016/j.parkreldis.2018.10.002. Epub 2018 Oct 1.

PMID:
30292732
18.

Altered driving performance of symptomatic Huntington's disease gene carriers in simulated road conditions.

Jacobs M, Hart EP, Miranda YM, Groeneveld GJ, van Gerven JMA, Roos RAC.

Traffic Inj Prev. 2018;19(7):708-714. doi: 10.1080/15389588.2018.1497796. Epub 2018 Oct 1.

PMID:
30273496
19.

Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease.

Andrews SC, Craufurd D, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Stout JC.

Neuropsychology. 2018 Nov;32(8):958-965. doi: 10.1037/neu0000479. Epub 2018 Sep 13.

PMID:
30211612
20.

Structural and functional changes of the visual cortex in early Huntington's disease.

Coppen EM, Grond JV, Hafkemeijer A, Barkey Wolf JJH, Roos RAC.

Hum Brain Mapp. 2018 Dec;39(12):4776-4786. doi: 10.1002/hbm.24322. Epub 2018 Aug 24.

PMID:
30144208
21.

Repeat length variations in polyglutamine disease-associated genes affect body mass index.

Gardiner SL, de Mutsert R, Trompet S, Boogaard MW, van Dijk KW, Jukema PJW, Slagboom PE, Roos RAC, Pijl H, Rosendaal FR, Aziz NA.

Int J Obes (Lond). 2019 Mar;43(3):440-449. doi: 10.1038/s41366-018-0161-7. Epub 2018 Aug 17.

PMID:
30120431
22.

Marriage as Protector for Nursing Home Admission in Huntington's Disease.

Winder JY, Achterberg WP, Roos RAC.

J Huntingtons Dis. 2018;7(3):251-257. doi: 10.3233/JHD-180305.

PMID:
30103341
23.

Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study.

Baake V, Coppen EM, van Duijn E, Dumas EM, van den Bogaard SJA, Scahill RI, Johnson H, Leavitt B, Durr A, Tabrizi SJ, Craufurd D, Roos RAC; Track-HD investigators.

Neuroimage Clin. 2018 Mar 27;19:66-70. doi: 10.1016/j.nicl.2018.03.033. eCollection 2018.

24.

Huntington's Disease Gene Expansion Carriers Are Aware of Their Degree of Apathy.

Baake V, van Duijn E, Roos RAC.

J Neuropsychiatry Clin Neurosci. 2018 Summer;30(3):183-187. doi: 10.1176/appi.neuropsych.18020031. Epub 2018 May 30.

PMID:
29843585
25.

The visual cortex and visual cognition in Huntington's disease: An overview of current literature.

Coppen EM, van der Grond J, Hart EP, Lakke EAJF, Roos RAC.

Behav Brain Res. 2018 Oct 1;351:63-74. doi: 10.1016/j.bbr.2018.05.019. Epub 2018 May 21. Review.

PMID:
29792890
26.

Does arterial hypertension influence the onset of Huntington's disease?

Valcárcel-Ocete L, Fullaondo A, Alkorta-Aranburu G, García-Barcina M, Roos RAC, Hjermind LE, Saft C, Frontali M, Reilmann R, Rickards H; REGISTRY investigators of the European Huntington’s Disease Network (EHDN), Zubiaga AM, Aguirre A.

PLoS One. 2018 May 23;13(5):e0197975. doi: 10.1371/journal.pone.0197975. eCollection 2018.

27.

Testing a longitudinal compensation model in premanifest Huntington's disease.

Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, Johnson EB, Durr A, Roos RAC, Leavitt BR, Mills JA, Stout JC, Scahill RI, Tabrizi SJ, Rees G; Track-On investigators.

Brain. 2018 Jul 1;141(7):2156-2166. doi: 10.1093/brain/awy122.

28.

Natural biological variation of white matter microstructure is accentuated in Huntington's disease.

Gregory S, Crawford H, Seunarine K, Leavitt B, Durr A, Roos RAC, Scahill RI, Tabrizi SJ, Rees G, Langbehn D, Orth M.

Hum Brain Mapp. 2018 Sep;39(9):3516-3527. doi: 10.1002/hbm.24191. Epub 2018 Apr 22.

29.

Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.

van Roon-Mom WMC, Roos RAC, de Bot ST.

Nucleic Acid Ther. 2018 Apr;28(2):59-62. doi: 10.1089/nat.2018.0720. Epub 2018 Mar 13.

PMID:
29620999
30.

Atrophy of the putamen at time of clinical motor onset in Huntington's disease: a 6-year follow-up study.

Coppen EM, van der Grond J, Roos RAC.

J Clin Mov Disord. 2018 Mar 23;5:2. doi: 10.1186/s40734-018-0069-3. eCollection 2018.

31.

Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease.

Minkova L, Gregory S, Scahill RI, Abdulkadir A, Kaller CP, Peter J, Long JD, Stout JC, Reilmann R, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S; TRACK-HD Investigators.

Neuroimage Clin. 2017 Oct 25;17:312-324. doi: 10.1016/j.nicl.2017.10.023. eCollection 2018.

32.

Premanifest Huntington's disease: Examination of oculomotor abnormalities in clinical practice.

Winder JY, Roos RAC.

PLoS One. 2018 Mar 1;13(3):e0193866. doi: 10.1371/journal.pone.0193866. eCollection 2018.

33.

Progressive microstructural changes of the occipital cortex in Huntington's disease.

Odish OFF, Reijntjes RHAM, van den Bogaard SJA, Roos RAC, Leemans A.

Brain Imaging Behav. 2018 Dec;12(6):1786-1794. doi: 10.1007/s11682-018-9849-5.

34.

Neurofilament light protein in blood predicts regional atrophy in Huntington disease.

Johnson EB, Byrne LM, Gregory S, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RA, Zetterberg H, Tabrizi SJ, Scahill RI, Wild EJ; TRACK-HD Study Group.

Neurology. 2018 Feb 20;90(8):e717-e723. doi: 10.1212/WNL.0000000000005005. Epub 2018 Jan 24.

35.

The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.

Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, Marcinkowski JT, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2018 Apr;49:42-47. doi: 10.1016/j.parkreldis.2018.01.006. Epub 2018 Jan 5.

PMID:
29326033
36.

Cognitive Performance and Apathy Predict Unemployment in Huntington's Disease Mutation Carriers.

Jacobs M, Hart EP, Roos RAC.

J Neuropsychiatry Clin Neurosci. 2018 Summer;30(3):188-193. doi: 10.1176/appi.neuropsych.17070144. Epub 2018 Jan 12.

PMID:
29325477
37.

Huntingtin gene repeat size variations affect risk of lifetime depression.

Gardiner SL, van Belzen MJ, Boogaard MW, van Roon-Mom WMC, Rozing MP, van Hemert AM, Smit JH, Beekman ATF, van Grootheest G, Schoevers RA, Oude Voshaar RC, Roos RAC, Comijs HC, Penninx BWJH, van der Mast RC, Aziz NA.

Transl Psychiatry. 2017 Dec 11;7(12):1277. doi: 10.1038/s41398-017-0042-1. Review.

38.

Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes.

McColgan P, Gregory S, Seunarine KK, Razi A, Papoutsi M, Johnson E, Durr A, Roos RAC, Leavitt BR, Holmans P, Scahill RI, Clark CA, Rees G, Tabrizi SJ; Track-On HD Investigators.

Biol Psychiatry. 2018 Mar 1;83(5):456-465. doi: 10.1016/j.biopsych.2017.10.019. Epub 2017 Oct 26.

39.

Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.

Coppen EM, Jacobs M, van den Berg-Huysmans AA, van der Grond J, Roos RAC.

Parkinsonism Relat Disord. 2018 Jan;46:56-61. doi: 10.1016/j.parkreldis.2017.11.001. Epub 2017 Nov 2.

PMID:
29128164
40.

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease.

Johnson EB, Gregory S, Johnson HJ, Durr A, Leavitt BR, Roos RA, Rees G, Tabrizi SJ, Scahill RI.

Front Neurol. 2017 Oct 10;8:519. doi: 10.3389/fneur.2017.00519. eCollection 2017.

41.

Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.

Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ; Track-HD and Track-On Investigators.

JAMA Neurol. 2017 Nov 1;74(11):1352-1360. doi: 10.1001/jamaneurol.2017.2107.

42.

[Driving with Alzheimer's disease].

Jacobs M, 't Hart EP, Roos RAC.

Ned Tijdschr Geneeskd. 2017;161:D1881. Dutch.

PMID:
28914216
43.

Design optimization for clinical trials in early-stage manifest Huntington's disease.

Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C; TRACK-HD Investigators.

Mov Disord. 2017 Nov;32(11):1610-1619. doi: 10.1002/mds.27122. Epub 2017 Sep 14.

44.

Cognitive decline in Huntington's disease expansion gene carriers.

Baake V, Reijntjes RHAM, Dumas EM, Thompson JC; REGISTRY Investigators of the European Huntington's Disease Network, Roos RAC.

Cortex. 2017 Oct;95:51-62. doi: 10.1016/j.cortex.2017.07.017. Epub 2017 Aug 3.

PMID:
28843844
45.

The reliability of commonly used electrophysiology measures.

Brown KE, Lohse KR, Mayer IMS, Strigaro G, Desikan M, Casula EP, Meunier S, Popa T, Lamy JC, Odish O, Leavitt BR, Durr A, Roos RAC, Tabrizi SJ, Rothwell JC, Boyd LA, Orth M.

Brain Stimul. 2017 Nov - Dec;10(6):1102-1111. doi: 10.1016/j.brs.2017.07.011. Epub 2017 Jul 31.

PMID:
28807846
46.

Body weight is a robust predictor of clinical progression in Huntington disease.

van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA.

Ann Neurol. 2017 Sep;82(3):479-483. doi: 10.1002/ana.25007. Epub 2017 Aug 22.

PMID:
28779551
47.

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.

Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ.

Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

48.

Large normal-range TBP and ATXN7 CAG repeat lengths are associated with increased lifetime risk of depression.

Gardiner SL, van Belzen MJ, Boogaard MW, van Roon-Mom WMC, Rozing MP, van Hemert AM, Smit JH, Beekman ATF, van Grootheest G, Schoevers RA, Oude Voshaar RC, Comijs HC, Penninx BWJH, van der Mast RC, Roos RAC, Aziz NA.

Transl Psychiatry. 2017 Jun 6;7(6):e1143. doi: 10.1038/tp.2017.116.

49.

Disease stage and plasma levels of cytokines in Huntington's disease: A 2-year follow-up study.

Bouwens JA, van Duijn E, Cobbaert CM, Roos RAC, van der Mast RC, Giltay EJ.

Mov Disord. 2017 Jul;32(7):1103-1104. doi: 10.1002/mds.26950. Epub 2017 May 29. No abstract available.

PMID:
28556406
50.

Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes.

Stuitje G, van Belzen MJ, Gardiner SL, van Roon-Mom WMC, Boogaard MW; REGISTRY Investigators of the European Huntington Disease Network, Tabrizi SJ, Roos RAC, Aziz NA.

Brain. 2017 Jul 1;140(7):e42. doi: 10.1093/brain/awx122. No abstract available.

PMID:
28549075

Supplemental Content

Support Center